Chapters

Transcript

Video

As shown in the ODYSSEY Outcomes Trial, alirocumab lowers Lp(a). FOURIER also demonstrated similar results with evolocumab. What are the implications of these findings and how do you translate the results into medical cardiology practice?

As shown in the ODYSSEY Outcomes Trial, alirocumab lowers Lp(a). FOURIER also demonstrated similar results with evolocumab. What are the implications of these findings and how do you translate the results into medical cardiology practice?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY